Novo Nordisk's Diabetes Drug Outshines Ozempic: Buy?
A new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
This guide demonstrates how to leverage historical returns to shape retirement-index-fund allocations and risk management.
21,803 articlesA new diabetes drug from Novo Nordisk could change the GLP-1 landscape. This deep dive breaks down what investors sho...
A historic 93% one-day rally in a well-known automaker set a record for the largest single-day stock gain, prompting ...
As fuel costs climb, airline stocks stumble and investors reassess 2026 earnings prospects. This piece breaks down wh...
Finding winning stocks isn’t about chasing the hottest trend. It’s about identifying durable catalysts, solid fundame...
IBM's shares sank as Anthropic's Claude Code intensifies AI competition, pushing ibm’s stock heads worst for a month ...
Snow-season demand shapes profitability for snow equipment makers. This article breaks down douglas dynamics (plow) e...
When an investment firm Absoluto Partners reveals a fresh stake in MercadoLibre, traders take note. This in-depth gui...
Bitcoin, Ethereum, and Solana jumped as analysts flagged a pause in the '10 a.m. dump' after a Jane Street lawsuit, m...
Dubai is poised to test a new era of urban travel with Uber and Joby Aviation. This article breaks down what the 2026...
Salesforce just delivered a solid quarter with revenue and adjusted earnings topping expectations and a $50 billion b...
Cava shares surge upbeat after a brighter outlook from the fast-casual chain. This article breaks down what’s behind ...
Oil prices rose modestly despite the Strait of Hormuz disruption, with traders watching for how long flows stay block...